TSC1 as a therapeutic target in mTOR driven triple negative breast cancer 2770

Abstract Description Triple-negative breast cancer (TNBC) is an aggressive malignancy with limited therapeutic options, necessitating the identification of novel biomarkers and therapeutic targets. Using bioinformatics analysis, we identified ZFHX4, TSC1, and CAMTA1 as candidate biomarkers based on high SNP counts and gene expression levels in TNBC datasets. ZFHX4, a transcription factor linked to tumor invasiveness and poor prognosis, and CAMTA1, associated with epigenetic regulation and altered in cancers, showed negligible expression in validation studies. In contrast, TSC1, a key regulator of the mTOR signaling pathway, demonstrated significant upregulation in the HCC1937 cell line, confirmed via qPCR and gene sequencing. TSC1’s role in regulating cell growth and metabolism suggests it may drive TNBC progression and contribute to immune evasion within the tumor microenvironment. While this study highlights TSC1 as a promising biomarker and potential therapeutic target for mTOR pathway inhibitors and immunomodulatory approaches, ongoing investigations will focus on elucidating TSC1’s functional role and evaluating additional candidate genes to uncover broader insights into TNBC pathogenesis and precision medicine strategies. Topic Categories Computational and Systems Immunology (COMP)